Nelivaptan is under clinical development by HMNC and currently in Phase II for Major Depressive Disorder. According to GlobalData, Phase II drugs for Major Depressive Disorder have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Nelivaptan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nelivaptan overview
Nelivaptan (NB-415, SSR-149415) is under development for the treatment of depression including major depressive disorder (MDD). The drug candidate targets vasopressin receptor 1B ((V1bR). It is administered through oral route in the form of capsule. It is being developed based on artificial intelligence platform.
HMNC overview
HMNC (HMNC Brain Health) is a precision psychiatry biopharma company that develops innovative therapies for mental health disorders. Its pipeline products include Ketabon, Nelivabon and Cortibon. The company’s lead products Ketabon, which treats Oral prolonged release formulation of Ketamine; Nelivabon for Vasopressin V1b antagonist and test and Cortibon treats CRH1-receptor antagonist and test. Its other program includes standalone pharmacogenomic test ABCB1 and PTSD blood test. HMNC Brain Health uses AI platform, combining psychiatry, genomics and analytics for the development of mental health disorder therapies. It has an operational presence in Germany and the US. HMNC Brain Health is headquartered in Munich, Bavaria, Germany.
For a complete picture of Nelivaptan’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
